In Vitro Efficacy Testing Services for Hyperparathyroidism

We provide robust and sensitive in vitro screening and characterization platforms for accelerating the discovery and screening of potential therapies for Hyperparathyroidism. Our services enable the evaluation of drug candidates targeting pathological processes associated with abnormal parathyroid hormone (PTH) secretion and calcium homeostasis dysregulation. Key targets include the parathyroid hormone receptor (PTH1R), vitamin D receptor (VDR), and related intracellular signaling pathways. We assess compound effects on hormone binding, receptor activation, gene expression, and cellular responses relevant to the pathophysiology of Hyperparathyroidism.

Our suite of in vitro testing methods encompasses biochemical, cell-based, radioligand binding, and reporter assays tailored to Hyperparathyroidism research. These approaches allow for comprehensive evaluation of compound efficacy, receptor interactions, and downstream functional responses, supporting both early screening and detailed mechanistic studies.

Calcitriol as substrate: Utilized to assess interactions with the vitamin D receptor and downstream signaling relevant to calcium metabolism.

Cell counting assay: Measures the proliferative or cytotoxic effects of compounds on relevant cell populations.

Chemiluminescent assay: Detects specific biomolecular interactions or signaling events using light emission for sensitive quantification.

Competitive binding assay: Determines the ability of compounds to compete with labeled ligands for receptor binding sites, indicating affinity and specificity.

Displacement of [125I]-[Nle8,18,Tyr34]-parathormone(1-34): Evaluates compound binding to the PTH receptor by measuring displacement of a radiolabeled PTH analog.

Displacement of [125I]-calcitriol: Assesses the binding affinity of compounds for the vitamin D receptor by radioligand displacement.

Displacement of [3H]-calcitriol: Similar to the above, uses tritiated calcitriol to quantify competitive binding interactions.

Dye assay: Employs colorimetric dyes to monitor cell viability, proliferation, or metabolic activity.

Fluorescent (Aequorin) assay: Measures intracellular calcium flux using the calcium-sensitive photoprotein aequorin, indicating receptor activation.

Fluorescent assay: General fluorescent-based detection for various cellular or molecular endpoints, including signaling or viability.

Fluorescent polarization assay: Quantifies binding interactions by measuring changes in fluorescence polarization upon ligand-receptor interaction.

Gene reporter assay: Evaluates transcriptional activity and downstream gene expression triggered by receptor activation.

Homogeneous Time Resolved Fluorescence (HTRF) assay: Sensitive, mix-and-read assay for detecting biomolecular interactions using time-resolved fluorescence.

Luciferine/luciferase assay: Monitors gene expression or cellular activity via luminescence from luciferase reporter systems.

RNA assay: Detects and quantifies RNA levels to measure gene expression changes in response to test compounds.

Radioactivity assay: Measures radiolabeled ligand binding or uptake, providing quantitative data on compound-receptor interactions.

Receptor selection/amplification technology assay: Identifies and amplifies cells expressing functional target receptors for high-specificity screening.

SRC-1 peptide recruitment assay: Evaluates recruitment of steroid receptor coactivator-1 to nuclear receptors, indicating agonist or antagonist activity.

We measure a comprehensive set of pharmacological parameters to quantify compound potency, efficacy, and binding characteristics. These parameters are essential for ranking candidate molecules, understanding structure-activity relationships, and guiding lead optimization in drug development.

EC-50: The concentration of a compound that produces 50% of its maximal effect, indicating potency.

IC-50: The concentration required to inhibit a biological or biochemical function by 50%, used to assess antagonist or inhibitor effectiveness.

Kd: The equilibrium dissociation constant, representing the affinity between a ligand and its receptor.

Ki: The inhibition constant, quantifying inhibitor binding affinity in competitive binding assays.

MEC: Minimum effective concentration, the lowest dose at which a compound elicits a measurable effect.

MIC: Minimum inhibitory concentration, the lowest concentration required to suppress a specific biological activity.

pA-2: Negative logarithm of the antagonist concentration that requires doubling the concentration of agonist to achieve the same effect; a measure of antagonist potency.

pEC-50: Negative logarithm of the EC-50, often used for easier comparison of compound potencies.

pIC-50: Negative logarithm of the IC-50, enabling straightforward comparison of inhibitory potencies.

pKb: Negative logarithm of the equilibrium constant for antagonist binding to receptors, reflecting antagonist affinity.

pKi: Negative logarithm of the Ki value, widely used for comparing inhibitor affinities across compounds.

Recommended In Vitro Efficacy Tests

Androgen Receptor

Androgen Receptor (AR) testing in hyperparathyroidism drug development evaluates AR’s regulatory role in parathyroid hormone expression and calcium homeostasis. This testing is vital for identifying compounds that modulate AR activity, aiding targeted therapy development. Using luciferin/luciferase reporter assays, we analyze compound efficacy and potency by measuring key parameters including MIC (minimum inhibitory concentration), Kd (binding affinity), and IC-50 (half-maximal inhibitory concentration).

Calcium Sensing Receptor

The Calcium Sensing Receptor (CaSR) regulates parathyroid hormone secretion; its dysfunction is central to hyperparathyroidism. CaSR testing is crucial for developing targeted therapies. We offer robust functional assays—including HTRF, fluorescent (including Aequorin), radioactivity, chemiluminescent, receptor selection/amplification, and gene reporter assays—to evaluate drug effects on CaSR activity. Key pharmacological parameters measured are pKb, pEC-50, EC-50, IC-50, and pIC-50, enabling precise potency and efficacy profiling.

Cytochrome P450 Family 24 Subfamily A Member 1

Cytochrome P450 Family 24 Subfamily A Member 1 (CYP24A1) regulates vitamin D metabolism, impacting calcium homeostasis in hyperparathyroidism. Testing CYP24A1 activity is crucial for developing targeted therapies. Using a radioactivity assay with calcitriol as substrate, this service measures compound potency via IC-50 values, enabling precise evaluation of drug candidates' effects on CYP24A1-mediated vitamin D catabolism.

Parathyroid Hormone 1 Receptor

Parathyroid Hormone 1 Receptor (PTH1R) is central to calcium regulation and pathogenesis of hyperparathyroidism. Testing PTH1R is vital for developing targeted therapies. Our assay utilizes displacement of [125I]-[Nle8,18,Tyr34]-parathormone(1-34) to assess ligand-receptor binding. Key parameters measured include inhibition constant (Ki), antagonist potency (pA-2), and binding affinity (pKi), providing crucial data for drug candidate evaluation and optimization.

Solute Carrier Family 9 Member A3

Solute Carrier Family 9 Member A3 (SLC9A3) regulates sodium and proton exchange, influencing calcium homeostasis and parathyroid hormone (PTH) secretion. Abnormal SLC9A3 activity is implicated in hyperparathyroidism. Testing SLC9A3 using a fluorescent assay enables efficient screening of drug candidates by measuring transporter inhibition. The main parameter assessed is IC50, indicating the compound concentration required to inhibit SLC9A3 activity by 50%, critical for hyperparathyroidism drug development.

Vitamin D Receptor

Our Vitamin D Receptor (VDR) testing service supports hyperparathyroidism drug development by evaluating VDR’s role in calcium regulation and parathyroid hormone expression. Accurate VDR assessment is vital for identifying effective modulators. Using advanced methods—such as SRC-1 peptide recruitment, fluorescent polarization, radioligand displacement, gene reporter, and chemiluminescent assays—we determine key pharmacological parameters including EC-50, MEC, Ki, and IC-50, ensuring precise compound characterization and optimal lead selection.